Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.46 |
| ▸ | MGLL | Q99685 | 4/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153258 | 0.87 | RET (0.43) | RETMGLLPIK3CAPIK3CD | |
| SCHEMBL18713230 | 0.87 | RET (0.49) | RETMGLLPIK3CAFFAR2PIK3CD | |
| SCHEMBL18705128 | 0.84 | RET (0.46) | RETMGLLPIK3CA | |
| SCHEMBL18390350 | 0.84 | RET (0.46) | RETMGLLPIK3CAPIK3CD | |
| SCHEMBL18390348 | 0.82 | MGLL (0.47) | RETMGLLPIK3CAFFAR2 | |
| SCHEMBL20349518 | 0.82 | RET (0.45) | RETMGLLPIK3CA | |
| SCHEMBL20970811 | 0.82 | RET (0.46) | RETMGLLPIK3CAPIK3CD | |
| SCHEMBL20070594 | 0.79 | CPS1 (0.48) | RETALDH1A1L3MBTL1 | |
| SCHEMBL20070456 | 0.74 | MGLL (0.46) | RETMGLLPIK3CAPIK3CDALDH1A1 | |
| SCHEMBL20070450 | 0.73 | RET (0.46) | RETMGLLFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885MGLL 4881/4885PIK3CA 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.